The study team from IncellDx Inc-USA, Lawrence General Hospital-Massachusetts, 3Bio-Rad-USA, Langone Medical Center-New York University-USA, Universidad de Costa Rica-Costa Rica, Avrok Laboratories Inc-USA and Oregon Health and Science University-USA published their preliminary findings as an abstract in the peer reviewed journal: Frontiers in Immunology.
https://www.frontiersin.org/articles/10.3389/fimmu.2021.746021/abstract
The underlying mechanism and source of this distinct immunologic condition three months or more after initial infection remains elusive. Here, we investigated the presence of SARS-CoV-2 S1 protein in 46 individuals. We analyzed T-cell, B-cell, and monocytic subsets in both severe COVID-19 patients and in patients with post-acute sequelae of COVID-19 (PASC).
A statistically significant number of non-classical monocytes contained SARS-CoV-2 S1 protein in both severe (P=0.004) and PASC patients (P=0.02) out to 15 months post-infection.
Non-classical monocytes were sorted from PASC patients using flow cytometric sorting and the SARS-CoV-2 S1 protein was confirmed by mass spectrometry.
No full length sequences were identified, and no sequences that could account for the observed S1 protein were identified in any patient.
Non-classical monocytes are capable of causing inflammation throughout the body in response to fractalkine/CX3CL1 and RANTES/CCR5.
[…] Chronic COVID-19 may affect up to 30% of all infected individuals […]